Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome
This trial is active, not recruiting.
|Sponsor||University of Aarhus|
|Start date||November 1994|
|End date||October 1996|
|Trial size||54 participants|
|Trial identifier||NCT00625001, 1994/2424|
Turner Syndrome (TS) is associated with osteopenia and osteoporosis. Reduced bone mineral density (BMD) and increased risk of fractures are present in many younger and middle-aged women with TS. The objective is therefore to describe longitudinal changes in BMD in TS.
The study is an observational follow-up study. Examinations at baseline, after 5 and 10 years.
Bone mineral density is measured by dual energy x-ray absorptiometry (DEXA) and bone turnover by bone markers.
Main Outcome Measures: Bone mineral density (BMD; grams/ square centimetre) were measured at lumbar spine, hip and the non-dominant forearm.
Women with Turner syndrome
Healthy control women
Bone Mineral Density in columna lumbalis, collum femoris and distal ulnae Bone mineral density (BMD; grams/ square centimetre) were measured at lumbar spine, hip and the non-dominant forearm.
time frame: Evey 5 years
Female participants at least 18 years old.
- Turner syndrome verified by karyotyping
- untreated hypothyroidism or hyperthyroidism
- present or past malignant diseases
- clinical liver disease
- treatment with drugs known to interfere with bone metabolism (e.g. glucocorticoids)
|Official title||Long Term Follow-up of Bone Mineral Density in Hormone Treated Turner Syndrome|
Call for more information